Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
TerminatedNCT03917355
Official study titleStudy of the Link Between Patient/Psychiatrist Motor Synchronization and Treatment Adhesion in Patients With First Psychotic Episode, ASMASS Project
This study ended early.
In MontpellierSchizophreniaObservational studyAges 18–60
- Countries
- France
- Sponsor
- University Hospital, Montpellier
CompletedNCT02896374
Official study titleNormal and Abnormal Event Related Potentials During Attribution of Intentions to Others and Resolution of Emotional Conflicts in Schizophrenia
This study has finished and is no longer accepting participants.
In Le ChesnaySchizophreniaBehavioural studyAges 18–60
- Countries
- France
- Sponsor
- Versailles Hospital
WithdrawnNCT02603458
Official study titleA Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia
This study was withdrawn before enrollment.
Multiple locations, including BostonSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- NYU Langone Health
TerminatedNCT00931996
Official study titleClinical and Computational Studies of Dopamine Function in Schizophrenia
This study ended early.
In ChicagoSchizophreniaMedication studyAges 15–64
- Countries
- United States
- Sponsor
- University of Illinois Chicago
CompletedNCT02704962
Official study titleA Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia
This study has finished and is no longer accepting participants.
In Kaohsiung CitySchizophreniaMedication studyAges 18–55
- Countries
- Taiwan
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
WithdrawnNCT00964041
Official study titleEffects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.
This study was withdrawn before enrollment.
In BostonSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Massachusetts General Hospital (Hospital / academic medical center)
TerminatedNCT02144155
Official study titleOpen-label Study of the Long-Term Efficacy of Intranasal Oxytocin in Patients With Schizophrenia
This study ended early.
In San DiegoSchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- University of California, San Diego
CompletedNCT02219009
Official study titleA Multicenter, 8-week, Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adult Subjects With Schizophrenia Who Are Treated With Oral Aripiprazole
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
WithdrawnNCT00425815
Official study titleA Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia
This study was withdrawn before enrollment.
Multiple locations, including Los AngelesSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- University of California, Los Angeles
TerminatedNCT00506909
Official study titleDouble-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients
This study ended early.
In San DiegoSchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- David Feifel
CompletedNCT02568709
Official study titleEffects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In San FranciscoSchizophreniaMedication studyAges 18–40
- Countries
- United States
- Sponsor
- University of California, San Francisco
TerminatedNCT01244542
This study ended early.
Multiple locations, including BesançonSchizophreniaInterventional studyAges 18–55
- Countries
- France
- Sponsor
- University Hospital, Strasbourg, France